

SUPPLEMENTAL TABLE 2 (continued)

FDA-APPROVED THERAPEUTICS FOR THE TREATMENT OF CANCER

Cell-signaling Inhibitors

Approved Indication	Generic Name	Trade Name
certain type of breast cancer	abemaciclib	Verzenio
certain type of non-Hodgkin lymphoma	acalabrutinib	Calquence
HER2+ breast cancer	ado-trastuzumab emtansine	Kadcyla
certain type of lung cancer	afatinib	Gilotrif
certain form of lung cancer	alectinib	Alecensa
certain type of breast cancer	alpelisib*	Piqray
certain type of leukemia	bosutinib	Bosulif
certain type of melanoma	binimetinib and encorafenib	Braftovi and Mektovi
certain type of lung cancer	brigatinib	Alunbrig
certain type of metastatic ALK-positive lung cancer	ceritinib	Zykadia
colon cancer*; head and neck cancer	cetuximab	Erbitux
certain form of melanoma*	cobimetinib	Cotellic and Zelboraf
certain type of non-Hodgkin lymphoma	copanlisib	Aliqopa
specific lung cancers*	crizotinib	Xalkori
multiple cancers	dabrafenib	Tafinlar
certain type of lung cancer	dacomitinib*	Vizimpro
some leukemias	dasatinib	Sprycel
certain types of leukemia and non-Hodgkin lymphoma	duvelisib	Copiktra
certain type of bladder cancer	erdafatinib*	Balversa
some lung cancers*; pancreatic cancer	erlotinib	Tarceva
some pancreatic cancers; kidney cancer; noncancerous kidney tumors; HER2+ breast cancers; neuroendocrine tumors	everolimus	Afinitor
lung cancer	gefitinib	Iressa

certain type of leukemia	gilteritinib*	Xospata
certain type of leukemia	glasdegib	Daurismo
certain form of lymphoma and non-Hodgkin lymphoma	ibrutinib	Imbruvica
certain types of leukemia and lymphoma	idelalisib	Zydelig
some leukemias; stomach cancer; certain type of skin cancer	imatinib	Gleevec; Glivec
HER2+ breast cancers	lapatinib	Tykerb
NTRK-positive solid tumors	larotrectinib	Vitrakvi
certain type of lung cancer	lorlatinib*	Lobrena
certain types of leukemia	midostaurin*	Rydapt
certain form of lung cancer	necitumumab	Portrazza
certain type of breast cancer	neratinib	Nerlynx
some leukemias	nilotinib	Tasigna
soft tissue sarcoma	olaratumab	Lartruvo
certain form of lung cancer*	osimertinib	Tagrisso
certain subtype of breast cancer	palbociclib	Ibrance
colon cancer	panitumumab	Vectibix
HER2+ breast cancer	pertuzumab	Perjeta
certain types of leukemia	ponatinib	Iclusig
certain type of breast cancer	ribociclib	Kisqali
myelofibrosis	ruxolitinib	Jakafi
most common type of skin cancer	sonidegib	Odomzo
multiple cancers	trametinib	Mekinist
HER2+ breast cancer	trastuzumab	Herceptin
kidney cancer	temsirolimus	Torisel; Torisel
thyroid cancer	vandetanib	Caprelsa
certain type of blood cancer and melanoma*	vemurafenib	Zelboraf
most common type of skin cancer	vismodegib	Erivedge

* includes companion diagnostic

Some drugs are available in multiple formulations; these have only been listed once. Where multiple trade names are used, only the most common have been listed.

American Association for Cancer Research
(AACR) Cancer Progress Report 2019